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Abstract	
Motivation:	Prediction	of	phenotypes	from	high-dimensional	data	is	a	crucial	task	in	precision	biology	and	
medicine.	 Many	 technologies	 employ	 genomic	 biomarkers	 to	 characterize	 phenotypes.	 However,	 such	
elements	are	not	sufficient	to	explain	the	underlying	biology.	To	improve	this,	pathway	analysis	techniques	
have	been	proposed.	Nevertheless,	such	methods	have	shown	lack	of	accuracy	in	phenotypes	classification.	
Results: Here	we	propose	a	novel	methodology	called		MITHrIL		(Mirna	enrIched	paTHway	Impact	anaLysis)	
for	 the	analysis	of	 signaling	pathways,	which	has	built	on	 top	of	 the	work	of	Tarca	et	al.,	2009.	 	MITHrIL		
extends	pathways	by	adding	missing	regulatory	elements,	such	as	microRNAs,	and	their	 interactions	with	
genes.	The	method	takes	as	 input	 the	expression	values	of	genes	and/or	microRNAs	and	returns	a	 list	of	
pathways	 sorted	 according	 to	 their	 deregulation	 degree,	 together	 with	 the	 corresponding	 statistical	
significance	 (p-values).	Our	 analysis	 shows	 that	 	MITHrIL	 	 outperforms	 its	 competitors	 even	 in	 the	worst	
case.	In	addition,	our	method	is	able	to	correctly	classify	sets	of	tumor	samples	drawn	from	TCGA.	
Availability: MITHrIL		is	freely	available	at	the	following	URL:	http://alpha.dmi.unict.it/mithril/	
Introduction	
The	 prediction	 of	 phenotypes,	 such	 as	 diseases,	 or	 of	 responses	 to	 therapies	 from	 the	 large	 amount	 of	
genotypic	high-dimensional	data	obtained	through	Next-Generation	Sequencing	techniques	is	an	extremely	
important	task	in	translational	biology	and	precision	medicine.	However,	the	gap	between	current	analysis	
techniques	and	the	ability	to	obtain	accurate	knowledge	is	broad. 
High-throughput	 sequencing	 and	 gene	 profiling	 techniques	 are	 radically	 transforming	 medical	 research,	
allowing	the	full	monitoring	of	a	biological	system.	The	use	of	these	technologies	typically	generates	a	list	of	
differentially	expressed	elements	(i.e.	genes	or	microRNAs)	whose	behavior	varies	significantly	among	the	
phenotypes	under	examination. 
Furthermore,	 compared	 to	 traditional	 gene	 expression	 extraction	 techniques	 (eg.	 Microarray),	 deep	
sequencing	 methods,	 such	 as	 RNA-Seq,	 provide	 much	 larger	 lists	 of	 differentially	 expressed	 genes,	
increasing,	 therefore,	 the	 complexity	 of	 the	 analysis.	 The	 common	 approach	 to	 simplify	 and	 make	 the	
analysis	 of	 such	 data	more	 fruitful	 consisted	 in	 grouping	 genes	 into	 smaller	 sub-sets	 according	 to	 some	
relationship,	 leveraging	on	existing	knowledge-bases	 such	as	ontologies	or	pathways.	The	analysis	of	 this	
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type	 of	 data	 at	 the	 functional	 level	 is	 crucial	 since	 it	 allows	 a	 strong	 reduction	 of	 dimensionality,	 thus	
providing	greater	insights	on	the	biology	of	the	phenomenon	under	study	[1]. 
An	 extensive	 class	 of	 techniques	 known	 as	Pathway	Analysis	 [2]	 goes	 in	 this	 direction.	 In	 the	 past,	 such	
term	has	been	associated	to	the	analysis	of	ontological	terms,	protein-protein	interaction	(PPI)	networks,	or	
to	 the	 inference	 of	 gene	 regulatory	 networks	 from	 expression	 data.	 More	 recently,	 great	 interest	 has	
shifted	 toward	 a	 class	 of	 methods	 called	 Knowledge	 base-driven	 pathway	 analysis	 [3].	 Such	 methods	
leverage	 on	 existing	 databases,	 such	 as	 the	 Kyoto	 Encyclopedia	 of	 Gene	 and	 Genomes	 (KEGG)	 [4,	 5]	 or	
Pathway	Commons	[6],	to	identify	those	pathways	that	may	be	affected	by	the	expression	changes	in	the	
observed	 phenotype.	 Knowledge	 base-driven	 pathway	 analysis	 techniques	 can	 be	 grouped	 into	 three	
generations	of	approaches	[3]:	i)	Over-Representation	Analysis	(ORA);	ii)	Functional	Class	Scoring	(FCS);	iii)	
Pathway	Topology-based	(PT).	 
First-generation	methods	statistically	evaluate	 the	number	of	altered	genes	 in	a	pathway	with	 respect	 to	
the	set	of	all	analyzed	genes.	After	filtering	the	resulting	gene	set	of	an	expression	assessment	experiment,	
ORA	strategies	[7-13]	typically	divide	the	list	of	genes	according	to	the	pathway	each	gene	belongs	to.	By	
applying	an	hypothesis	test	(i.e.	hypergeometric,	chi-square,	or	binomial)	they	are	able	to	determine	if	the	
number	 of	 such	 genes	 is	 over-	 or	 under-represented.	 These	 methods,	 however,	 have	 some	 major	
limitations.	 Firstly,	 considering	 only	 the	 number	 of	 differentially	 expressed	 genes,	 while	 omitting	 their	
expression,	implies	that	the	magnitude	of	their	change	be	unimportant	for	pathway	activity.	Furthermore,	
considering	only	statistically	significant	differential	expression	may	exclude	those	genes	whose	coordinated	
alteration	may	 lead	 to	 remarkable	 effects,	 although	 their	 differential	 expression	may	 not	 be	 statistically	
significant.	Finally,	they	consider	individual	genes	and	pathways,	respectively,	in	an	manner	independent	of	
the	surrounding	biological	context,	eluding	what	truly	happens	in	reality.	
A	first	generation	method,	DIANA-miRPath	[14],	assesses	the	impact	of	miRNAs	in	biological	processes	by	
identifying	 the	 pathways	 in	 which	 they	 are	 significantly	 involved.	 The	 software	 employs	 a	 functional	
annotation	of	one	or	more	miRNAs	by	means	of	a	hypergeometric	distribution,	or	an	unbiased	empirical	
distribution,	 or	 a	 statistical	 meta-analysis.	 Moreover,	 it	 allows	 the	 identification	 of	 sub-sets	 of	 miRNAs	
which	significantly	regulates	a	collection	of	pathway,	on	the	basis	of	experimental	data.	
Second-generation	methods	 compensated	 some	 of	 the	 disadvantages	 of	 ORA	 approaches.	 Typically	 FCS	
methods	compute	a	gene-level	statistic	from	their	expression	levels,	by	means	of	a	statistical	approach	(i.e.	
ANOVA,	 Q-statistic,	 signal-to-noise	 ratio,	 t-test,	 or	 Z-score).	 Such	 a	 statistic	 is	 calculated	 considering	 all	
genes	 in	 a	 pathway	 [15-21]	 and	 its	 statistical	 significance	 is	 estimated	 through	 an	 appropriate	 null	
hypothesis	 [16,	22-24].	 FCS	methods	avoid	 some	of	 the	 limitations	of	 the	ORA	approaches	by	 ranking	all	
genes	through	their	expression	level	and	by	considering	the	dependencies	within	a	pathway.	However,	by	
using	 gene	 expression	 only	 to	 sort	 genes,	 they	 do	 not	 take	 into	 account	 the	 fact	 that	 such	 values	 can	
change	pathways	activity. 
In	order	to	overcome	the	disadvantages	of	FCS	methods,	the	third	class	of	techniques	models	a	pathway	as	
a	graph,	considering	 its	topology	when	computing	scores.	A	thorough	analysis	of	all	PT-based	approaches	
has	been	provided	in	[25]. 
In	Draghici	et	al.	[26],	an	analytical	technique	called	impact	factor	(IF)	was	introduced.	The	impact	factor	is	
a	pathway-level	score	that	takes	into	account	biological	factors	such	as	the	magnitude	of	change	in	genes	
expression,	 the	 type	of	 interactions	 between	 genes,	 and	 their	 location	 in	 the	 pathway.	 In	Draghici	 et	 al.	
[26],	 each	 pathway	 is	 modeled	 as	 a	 graph	 in	 which	 nodes	 represent	 genes,	 while	 edges	 represent	
interactions	between	them.	Authors	also	define	a	gene-level	 statistic	 (called	perturbation	 factor,	PF)	as	a	
linear	function	of	the	change	in	gene	expression	and	the	perturbation	of	its	neighborhood.	Such	a	statistic	
is	 then	 combined	 for	 each	 element	 in	 a	 pathway,	 and	 a	 p-value	 is	 computed	 by	 means	 of	 exponential	
distribution. 
The	analysis	method	presented	by	Draghici	et	al.	[26],	has	been	further	improved	by	the	SPIA	algorithm	[27]	
which	attenuates	the	dominant	effect	exercised	by	the	change	in	expression	within	PFs	computation,	while	
reducing	 the	 high	 rate	 of	 false	 positives	 when	 the	 input	 list	 of	 genes	 is	 small.	 SPIA	 uses	 a	 bootstrap	
procedure	 to	evaluate	 the	significance	of	 the	observed	perturbation	 in	 the	pathway.	All	 this	 is	 combined	
with	 a	 p-value	 computed	 in	 ORA	 style	 to	 make	 a	 full	 assessment	 of	 the	 statistical	 significance	 of	 the	
perturbation	of	each	pathway. 
To	 reduce	 the	 number	 of	 false	 positives,	 and	 to	 obtain	 a	 more	 significant	 analysis,	 Vaske	 et	 al.	 [28]		
presented	the	PARADIGM	algorithm,	which	has	been	further	improved	by	[29].	PARADIGM	is	a	method	to	
infer	 patient-specific	 genetic	 activity	 by	 incorporating	 information	 regarding	 interactions	 between	 genes	
provided	 in	 a	 pathway.	 The	 method	 predicts	 the	 degree	 of	 alteration	 in	 the	 activity	 of	 a	 pathway	 by	
employing	a	probabilistic	inference	algorithm.	The	authors	show	that	their	model	obtains	significantly	more	
reliable	results	than	SPIA.	However,	Mitrea	et	al.	[25]	stated	they	could	not	reproduce	the	results	reported	
in	Vaske	et	al.	[28],	despite	the	full	cooperation	of	its	authors.	
However,	both	SPIA	and	PARADIGM	completely	ignore	post-transcriptional	regulatory	interactions	enacted	
by	miRNAs.	To	 fill	 this	gap,	Calura	et	al.	developed	a	new	approach,	Micrographite	 [30],	which	 is	able	 to	
integrate	pathway	with	predicted	and	validated	miRNA-target	 interactions.	The	method,	by	performing	a	
topological	 analysis	 based	 on	 expression	 profiles,	 is	 able	 to	 identify	 significant	 gene	 circuits	 specific	 of	 a	
phenotype.	 The	 main	 advantage	 of	 the	 methodology	 is	 the	 ability	 to	 accurately	 describe	 the	 cellular	
scenario	that	led	to	the	input	expression	data.	
Here,	we	present	MITHrIL	(miRNA	enriched	pathway	impact	analysis),	a	technique	that	extends	the	method	
in	 [26]	 and	 SPIA	 [27],	 by	 combining	 their	 effectiveness	 and	 improves	 the	 reliability	 of	 the	 results.	 The	
strength	 of	 MITHrIL	 lies	 in	 the	 enrichment	 of	 pathways	 with	 information	 regarding	 microRNAs,	 post-
transcriptional	regulatory	elements	whose	addition	is	clearly	essential	to	the	greater	meaningfulness	of	the	
results.	Our	method,	starting	from	expression	values	of	genes	and/or	microRNAs,	returns	a	list	of	pathways	
sorted	 according	 to	 the	 degree	 of	 their	 de-regulation,	 together	 with	 the	 corresponding	 statistical	
significance	 (p-values),	 and	 a	 predicted	 degree	 of	 alteration	 for	 each	 endpoint	 (a	 pathway	 node	 whose	
alteration,	based	on	current	knowledge,	affects	the	phenotype	in	a	specific	way).	
To	 evaluate	 our	 algorithm,	we	 used	 the	 decoy	 pathway	methodology	 introduced	 in	 Vaske	 et	 al.	 [28]	 on	
expression	datasets	obtained	from	The	Cancer	Genome	Atlas.	We	showed	that	adding	information	on	the	
otherwise	missing	regulatory	elements	proves	to	be	pivotal	in	improving	the	reliability	of	pathway	analysis	
methodologies.	As	further	evidence	of	the	reliability	of	our	pathway	impact	analysis	method,	we	employed	
our	algorithm	for	the	classification	of	phenotypes.	The	results	highlight	the	ability	of	our	methodology	to	
strongly	reduce	the	dimensionality	of	the	data	while	maintaining	a	very	high	classification	quality. 
Results	
Biological	 soundness.	We	compared	our	methodology	with	PARADIGM	 [28],	SPIA	 [27]	and	Micrographite	
[30]	by	employing	the	technique	defined	in	Vaske	et	al.	2010.	The	aim	is	to	establish	whether	the	ranking	
computed	with	a	pathway	analysis	algorithm	is	biologically	significant.	This	is	achieved	by	defining	random	
pathways	(called	decoy	pathways)	with	the	same	topology	as	the	real	ones	but	randomly	selected	nodes.	
All	 pathways	 are	 then	 evaluated	 by	 each	 algorithm,	 estimating	 the	 ability	 of	 each	 method	 to	 properly	
separate	decoy	pathways	 from	 real	 ones	by	means	of	 a	 receiver	operating	 characteristic	 (ROC)	 curve.	 In	
principle,	 a	 method	 that	 can	 correctly	 distinguish	 real	 pathways	 from	 decoys	 should	 yield	 biologically	
significant	results.	
We	 performed	 comparisons	 between	MITHrIL,	 SPIA,	 PARADIGM	 and	Micrographite	on	 a	 set	 of	 selected	
cancer	 types	 (see	 Table	 1).	 Such	 a	 comparison	 allowed	 us,	 by	 ranking	 the	 datasets	 according	 to	
performance,	 to	 identify	 the	 single	 cancer	 type	 in	 which	 our	 algorithm	 had	 the	 lowest	 quality	 results,	
namely,	Lung	squamous	cell	carcinoma	(LUSC). 
The	results	of	the	four	methodologies	were	ranked	as	follows:	PARADIGM	according	to	the	average	number	
of	significant	scores,	as	described	in	[28];	SPIA	according	to	the	adjusted	p-value	as	obtained	through	their	
software	implementation;	Micrographite	according	to	the	pathway	prioritization	phase;		MITHrIL	according	
to	the	adjusted	p-value	and	the	accumulator.	More	precisely,	in	MITHril,	all	the	results	are	sorted	first	by	p-
value	 and,	 thereafter,	 in	 the	 presence	 of	 equal	 p-values	 their	 corresponding	 accumulator	 is	 taken	 into	
account	 to	 determine	 their	 order.	 In	 Supplementary	 Figures	 1-3,	 we	 present	 the	 results	 of	 the	 detailed	
comparison	in	each	TCGA	dataset.	Out	analysis	clearly	shows	that	MITHrIL	gives	the	best	performances.	As	
further	proof	of	the	goodness	of	our	methodology,	we	computed	the	average	area	under	each	ROC	curve	
(AUC).	The	results	were	summarized	in	Figure	1	(more	details	can	be	found	in	Supplementary	Table	1).	The	
four	 boxes	 in	 the	 figure	 represent	 the	 AUC	 variability	 range	 for	 the	 four	 compared	 methodologies,	
respectively.	
Prediction	 of	 cancer	 types.	We	 also	 evaluated	 our	 algorithm	 by	 assessing	 its	 performances	 in	 terms	 of	
capability	to	predict	the	cancer	type.	To	do	this,	we	elected	to	train	the	PAMr	[31]	classification	algorithm	
and	evaluated	its	performance	by	means	of	a	10-fold	cross	validation	(CV)	procedure.	PAMr	is	an	approach	
devised	 to	predict	 cancer	 class	 from	gene	expression	profiling,	based	on	an	enhancement	of	 the	nearest	
shrunken	centroid	classifier.	The	algorithm	is	able	to	 identify	subsets	of	genes	that	best	characterize	each	
class.	The	technique	 is	general	and	can	be	used	 in	many	other	classification	problems.	The	CV	procedure	
takes	as	 input	all	 the	feature	profiles	of	each	patient,	and	divides	them	into	10	subsets,	by	balancing	the	
elements	of	each	class	in	each	subset.	A	subset	is,	then,	removed	(test	set),	and	the	classifier	is	trained	on	
the	remaining	nine	sets	(training	set),	in	order	to	prioritize	and	select	the	features.	Each	profile	in	the	test	
set	is	then	classified,	and	the	results	are	used	to	estimate	the	error.	The	methodology	is	repeated	so	that	
each	subset	is	used	once	as	the	test	set.	The	CV	procedure	was	designed	in	order	to	remove	overfitting	and	
overestimation	of	the	results.		
A	 reference	 classification	was	 thus	 established	 by	 applying	 such	 a	 procedure	 to	 the	 Log-Fold-Change	 of	
differentially	 expressed	 genes	 of	 our	 cancer	 cases.	 The	 rationale	 behind	 such	 a	 choice	 is	 to	 show	 that	
pathway	perturbation,	which	takes	into	account	network	structure,	increases	the	biologically	soundness	of	
the	results	with	respect	to	a	plain	Log-Fold-Change-based	approach,	widely	used	as	a	gold	standard.	First	
we	computed	all	differentially	expressed	genes	for	each	tumor	type,	obtaining	a	total	of	17,326	genes	that	
appear	 to	 be	 de-regulated	 in	 at	 least	 one	 disease.	 Next,	 we	 calculated	 their	 Log-Fold-Change	 in	 each	
sample,	 trained	 a	 classifier	 and	 verified	 its	 performance	 using	 the	 above	 described	 CV	 procedure.	 The	
results	 (Table	 2)	 demonstrate	 that	 such	 a	 classification	 is	 quite	 reliable	 since	 it	 yields	 a	 very	 small	 error.	
Notice	that	Micrographite	is	not	able	to	compute	pathway	ranking	for	a	single	sample,	therefore	we	did	not	
perform	any	classification	using	such	a	method.	Hence,	we	ran	MITHrIL,	SPIA	and	PARADIGM	on	all	samples	
of	our	set	of	selected	cancer	types,	and	trained	three	classification	models	using	total	accumulation	scores. 
As	 before,	 we	 performed	 a	 10-fold	 cross	 validation	 and	 evaluated	 errors	 in	 each	 class	 (Table	 2).	
Furthermore,	leveraging	the	ability	of	MITHrIL	and	PARADIGM	to	return	the	perturbation	for	each	of	3,165	
pathway	endpoints,	we	trained	additional	classifiers	based	on	such	values.	Since	SPIA	computes	pathway-
level	 statistic	 by	 means	 of	 a	 linear	 equation	 system,	 it	 could	 not	 return	 perturbations	 of	 endpoints.	
Therefore	 we	 elected	 to	 use	 MITHrIL	 without	 miRNAs	 to	 establish	 the	 classification	 performances	 of	
endpoints,	when	such	elements	are	missing.	
Our	analysis	 clearly	 shows	 that	performances	are	considerably	 improved	over	 reference	classification,	by	
taking	into	account	endpoint	perturbations	(Table	2).	Moreover,	we	can	notice	a	significant	dimensionality	
reduction	of	our	data,	since	by	using	perturbation	of	pathway	endpoints,	computed	by	means	of	Equation	1	
(see	 the	 section	Materials	 and	Method),	 we	 are	 able	 to	 train	 PAMR	 on	 about	3165	genes	 (18%	of	 the	
number	of	differentially	expressed	ones). 
Table	2	reports	also	the	classifications	based	on	MITHrIL	pathway	accumulators.	We	recall	that	accumulator	
summarizes,	with	a	single	value,	the	general	perturbation	we	observe	within	a	pathway.	Hence,	as	a	further	
effect	 this	 yields	 a	 stronger	 dimensionality	 reduction.	 Although	 we	 notice	 a	 slight	 increase	 in		
misclassification	error,	compared	to	reference	classification,	it	 is	important	to	highlight	that	we	were	able	
to	 reduce	 to	 237	 the	 number	 of	 features	 on	which	PAMR	 classifier	 was	 trained.	 Pathway	 Accumulators	
were	 computed	 according	 to	 Equation	 5. The	 last	 two	 columns	 of	 Table	 2	 report	 the	 classification	
performances	obtained	by	SPIA	accumulators	and	PARADIGM	scores.	All	of	this	shows	that	the	addition	of	
miRNA	 information	 is	 crucial	 in	order	 to	obtain	more	 reliable	 results.	Notice	 that	we	 cannot	deduce	any	
information	 about	 the	 performances	 of	 PARADIGM	 extended	with	microRNAs,	 since	 no	 implementation	
with	such	a	knowledge	is	available,	and	this	goes	beyond	the	scope	of	our	paper.	
To	 further	 highlight	 the	 biological	 relevance	 of	 endpoints,	 we	 performed	 a	 set	 of	 experiments	 with	
randomly	selected	nodes	within	pathways	(see	third	and	fourth	columns	of	Table	2).	The	results	show	that	
the	choice	of	endpoints	is	reasonable,	since	endpoints	synthetize	perturbations	of	upstream	nodes.		
Coherence	of	the	prediction	of	pathway	nodes	state.		As	a	further	validation	our	methodology,	we	chose	
to	 verify	 the	 percentage	 of	 endpoints	 for	 which	 a	 coherent	 prediction	 of	 the	 deregulation	 is	 obtained.	
Initially,	we	applied	MITHrIL	with	and	without	miRNAs	to	estimate	the	perturbations	for	each	endpoint	of	
each	sample	(excluding	the	expression	values	of	the	endpoints	 in	order	to	avoid	 introducing	a	bias	 in	our	
results).	Subsequently,	we	computed	the	percentage	of	endpoints	for	which	the	sign	of	perturbation	agrees		
with	that	of	the	log-Fold	Change.	This	validation	estimates	the	reliability	of	the	predictions	of	our	method	
and	the	importance	of	the	addition	of	miRNA	knowledge	to	our	model.	The	results	(Figure	2)	highlight	that	
plugging	 quantitative	 information	 on	 miRNAs	 is	 crucial	 to	 establish	 a	 far	 more	 comprehensive	 and	
meaningful	 estimation	 of	 phenotype	 activity.	 Therefore,	 using	 perturbation	 without	 miRNAs	 could	 be	
misleading.	
Discussion	
In	the	last	decade,	miRNAs	have	ever	more	revealed	to	be	crucial	 in	the	modulation	of	numerous	cellular	
pathways	via	the	exertion	of	their	important	regulatory	function	when	targeting	key	genes.	Since	the	first	
connection	between	miRNAs	and	cancer	was	made	in	2002	[32],	miRNA	deregulation	has	been	proven	to	
be	indeed	at	the	root	of	the	pathogenesis	of	all	cancers	[33].	It	suffices	to	consider,	for	instance,	how	the	
deregulation	of	even	a	single	miRNA	is	capable	to	cause	cancer,	as	in	the	case	of	miR-155	which	has	been	
shown	 to	 be	 responsible	 for	 the	 onset	 of	 Acute	 Lyphoblastic	 Leukemia/high-grade	 lymphoma	 in	mouse	
[34].	Additionally,	the	predominant	roles	played	by	miRs	21,	221	and	222	in	several	cancer	types	prove	the	
importance	 these	 small	 RNA	molecules	 have	 in	 tumor	 pathogenesis	 and	 progression,	while	 also	 being	 a	
determining	factor	 in	drug	resistance	[33].	 In	 light	of	 this	and	many	other	evidences	discovered	 in	recent	
years,	 the	 integration	of	miRNA	expression	when	evaluating	cancer	pathway	perturbation	has	become	of	
utmost	 importance.	 The	 proper	 consideration	 of	 the	 crucial	 effects	 yielded	 by	 the	 action	 of	 these	 small	
non-coding	 RNA	 molecules	 on	 overall	 gene	 expression	 indeed	 contributes	 to	 a	 more	 comprehensive	
depiction	 of	 the	 biological	 reality,	 providing	 a	 more	 accurate	 means	 for	 pathway	 assessment	 and	
phenotype	categorization.	 In	 fact,	 given	 the	very	 important	biological	 role	played	by	miRNAs,	 integrating	
their	evaluation	can	greatly	help	 in	 the	discernment	of	even	 fine	changes	 in	 the	cellular	gene	expression	
profile,	which	could	make	the	difference	between	a	normal	and	abnormal	phenotypes,	already	at	disease	
onset.	
Here	 we	 presented	 a	 novel	 knowledge	 base-driven	 pathway	 analysis	 methodology	 called	 MITHrIL.	 By	
enriching	KEGG	pathways	with	experimentally	validated	interactions	between	genes	and	miRNAs,		MITHrIL		
is	capable	to	clearly	improve	the	reliability	of	pathway-based	analysis	of	phenotypes.		
Through	 the	 enrichment	 with	 miRNA	 information,	MITHrIL	 can	 greatly	 improve	 predictions	 over	 SPIA,	
PARADIGM,	and	Micrographite.	In	fact,	while	the	other	methodologies	cannot	properly	distinguish	between	
decoy	pathways	and	real	ones,		MITHrIL		is	capable	of	obtaining	much	better	results.	Even	our	worst	case	
had	 superior	 results	 than	 our	 three	 competitors.	 From	 a	 biological	 standpoint,	 the	 ability	 to	 distinguish	
decoy	pathways	from	real	ones	addresses	the	fundamental	necessity	to	be	able	to	properly	 interpret	the	
actual	cellular	mechanisms	as	possessing	a	biological	criterion	which	is	crucial	to	the	life	of	the	cell	and	not	
the	result	of	random	phenomena.		
Therefore,	 we	 focused	 our	 analysis	 on	 the	 ability	 of	 our	methodology	 to	 synthesize	 information	 gained	
from	gene	expression	data	and	 thus	provide	novel	biological	 clues.	 For	 this	purpose,	by	using	 the	PAMR	
algorithm,	we	performed	different	 types	of	classification,	 taking	as	 reference	 the	 results	arising	 from	the	
classification	based	directly	on	Log-Fold-Changes.	Our	 findings	demonstrated	 the	capability	of	MITHrIL	 to	
synthesize	 biological	 information	 contained	 in	 the	 data,	 while	 yielding	 high	 classification	 accuracy.	
Furthermore,	MITHrIL	 greatly	 reduces	 the	dimensionality	of	data	of	 about	73	times	 compared	 to	a	naive	
Log-Fold-Change	based	method.	This	significant	dimensionality	reduction	may	also	make	the	analysis	more	
accurate	 since	 it	 could	 reduce	 the	 noise	 that	 can	 be	 introduced	 by	 the	 technologies	 used	 to	 gather	
expression	 data	 from	 samples.	 Furthermore,	 when	 knowing	 the	 phenotype	 that	 is	 being	 analyzed,	 it	 is	
possible	to	further	reduce	the	number	of	dimensions	by	focusing	only	on	those	pathways	that	are	known	to	
be	somehow	involved	in	it.	
Compared	 to	 SPIA,	 MITHrIL	 can	 also	 return	 the	 perturbation	 computed	 for	 pathway	 endpoints,	 whose	
subsequent	analysis	can	lead	to	important	additional	insights	about	the	biology	underlying	the	phenomena	
under	 study.	 Indeed,	 the	proper	evaluation	of	pathway	endpoints	 can	 contribute	 to	 a	 far	more	accurate	
phenotype	assessment,	as	a	more	detailed	diversification	between	pathological	phenotypes	at	the	pathway	
level	is	reflected	more	at	the	endpoints	rather	than	in	any	other	node	of	the	pathway	network.	This	allows	
to	more	 effectively	 distinguish	 pathologies	 sharing	 even	 a	 very	 similar	 set	 of	 deregulated	 genes	 (as	 you	
could	more	easily	distinguish	similar	yet	different	trees	more	easily	by	confronting	their	leaves	rather	than	
their	roots).	By	leveraging	on	endpoint	perturbation,	we	are	also	able	to	greatly	reduce	the	misclassification	
error,	although	we	are	able	to	reduce	data	dimensionality	by	only	5	times.	This	allows	us	to	stress	the	fact	
that	gene	perturbations	are	capable	to	discriminate	among	the	pathological	classes	of	our	data.	
Leveraging	 on	 the	 potential	 provided	 by	miRNA	 enrichment	 in	 pathway	 analysis,	 	MITHrIL	 	 represents	 a	
bioinformatic	resource	capable	of	a	far	more	accurate	evaluation	of	pathway	deregulation	 in	cancer.	This	
can	provide	a	decisive	contribution	to	cancer	 research	 in	 terms	of	directing	 researchers	more	effectively,	
reducing	costs	and	time	requirements.	Specifically,	MITHrIL	can	contribute	to	an	earlier	diagnosis,	an	early	
and	more	accurate	drug	resistance	assessment,	as	well	as	to	more	precise	prognosis	in	terms	of	predicting	
future	disease	development.	
Nevertheless,	our	results	can	be	further	improved	given	that	pathways	are	still	incomplete,	thus	potentially	
resulting	 in	 partial	 or	 erroneous	 conclusions.	 Future	 development	 in	 pathway	 analysis	 methodologies	
should	 take	 into	 account	 additional	 regulatory	 elements,	 such	 as	 long	 non-coding	 RNA	 (lncRNAs),	 along	
with	epigenetic	 information,	 such	as	methylation	patterns,	 variants,	 or	 copy	number	 variants.	Mutations	
could	be	exploited	by	considering	their	impact	on	the	modulation	of	𝛽	function	(see	the	section	Materials	
and	Method	 for	 the	 definition	 of	𝛽),	 for	 example	 by	 assessing	 the	 difference	 in	 interaction	 strength	 by	
means	of	 free	energy.	We	could	also	define	the	𝛽	function	by	evaluating	the	correlation	between	patient	
expression	profiles	and	corresponding	phenotype.	
Materials	and	Methods	
Pathway	Enrichment	Outline	
Our	methodology	distinguishes	itself	from	other	pathway	analysis	techniques	primarily	for	the	use	of	KEGG		
[4,	5]	pathways	enriched	with	microRNAs	(miRNAs)	and	their	interactions	with	genes.	 
In	order	 to	achieve	 this,	we	downloaded	all	 validated	 inhibition	 interactions	between	miRNA	and	 targets	
from	miRTarBase	 [35]	 and	miRecords	 [36].	We	 also	 obtained	 interactions	 between	 transcription	 factors	
(TFs)	and	miRNAs	 from	TransmiR	 [37].	By	 taking	 into	account	TFs	activating	miRNA	genes	we	are	able	 to	
increase	the	knowledge	stored	within	each	pathway.	We	then	standardized	all	identifiers	in	their	respective	
databases	to	avoid	duplicates.	The	mapping	of	miRNA	identifiers	was	performed	by	using	miRBase	release	
20	 [38-42]	 as	 reference	 database.	 For	 each	 target,	 we	 performed	 a	 twofold	mapping	 procedure:	 firstly,	
each	gene	identifier	has	been	converted	to	its	Entrez	one;	then,	by	taking	advantage	of	KEGG	REST	API,	we	
mapped	 each	 Entrez	 Id	 to	 the	 corresponding	 KEGG	 Id.	 This	 standardized	 list	 of	 interactions	 was,	 lastly,	
filtered	 to	 remove	 all	 duplicates.	 Such	 a	 procedure	 allowed	 us	 to	 build	 a	 knowledge	 base	 of	10,537	
experimentally	validated	interactions	between	385	miRNAs	and	3,080	genes. 
Pathway	enrichment	was	performed	by	defining	a	new	type	of	nodes	representing	miRNAs	in	the	pathway	
notation,	along	with	 two	 types	of	directed	edges,	 for	miRNA-target	 inhibition	 interactions	and	TF-miRNA	
interactions,	respectively.	The	enrichment	is	thus	performed	automatically	by	adding	to	each	pathway	only	
miRNAs	that	interact	with	at	least	one	element	within	it.	 
Finally,	in	order	to	acquire	information	on	which	endpoints	are	contained	in	each	pathway,	we	employed	a	
depth-first	 search	 algorithm	 (DFS)	 [43]	 to	 automatically	mark	which	 genes	 are	 located	 at	 the	 end	of	 the	
chains	of	reactions	in	each	pathway.	The	search	for	endpoints	in	a	pathway	starts	from	a	random	node.	The	
DFS	 algorithm	 follows	 the	 interactions	 down	 to	 the	 nodes	 from	 which	 no	 other	 one	 can	 be	 reached	
(putative	endpoints).	The	procedure	is	repeated	until	all	nodes	have	been	analyzed.	Putative	endpoints	are,	
then,	manually	 screened	 to	 determine	 if	 they	 are	 associated	with	 phenotypic	 changes	 as	 stated	 on	 the	
KEGG	database.	Only	 the	 latter	 are	 taken	 as	 pathway	 endpoint.	 An	 example	 of	 endpoints	 is	 reported	 in	
Supplementary	Figure	4. 
Algorithm	
Our	 methodology	 consists	 in	 an	 extension	 of	 Draghici	 et	 al.	 [26]	 and	 Tarca	 et	 al.	 [27].	 It	 requires	 a	
case/control	 expression	 data	 set	 from	 which	 statistically	 differentially	 expressed	 features	 have	 been	
extracted	 (genes,	miRNAs,	or	both).	For	 such	elements,	 the	computation	of	 their	 Log-Fold-Change	 is	also	
needed.	 Starting	 from	 such	 information,	MITHrIL	 computes,	 for	 each	 gene	 in	 a	 pathway,	 a	Perturbation	
Factor	 (PF),	 which	 is	 an	 estimate	 of	 how	 much	 its	 activity	 is	 altered	 considering	 its	 expression	 and	 1-
neighborhood.	 Positive	 (negative)	 values	 of	 PF	 indicate	 that	 the	 gene	 is	 likely	 activated	 (inhibited).	 By	
appropriately	 combining	 each	 PF	 of	 a	 pathway,	 our	 algorithm	 is,	 therefore,	 able	 to	 calculate	 an	 Impact	
Factor	 (IF)	 and	 an	Accumulator	 (Acc).	 The	 IF	 of	 a	 pathway	 is	 a	metric	 expressing	 how	 important	 are	 the	
changes	 detected	 in	 the	 pathway,	 the	 greater	 the	 value,	 the	most	 significant	 are	 the	 changes.	 The	Acc	
indicates	the	total	level	of	perturbation	in	the	pathway	and	the	general	tendency	of	its	genes:	positive	Acc	
values	indicate	a	majority	of	activated	genes	(or	inhibited	miRNAs),	while	negative	ones	corresponds	to	an	
abundance	 of	 inhibited	 genes	 (or	 activated	 miRNAs).	 To	 the	 Acc	 is	 also	 assigned	 a	 p-value	 which	 is	 an	
estimate	of	the	probability	of	getting	such	accumulator	by	chance.	Finally,	by	applying	the	[44]	method,	we	
estimate	the	false	discovery	rate	and	p-values	are	adjusted	on	multiple	hypotheses. 
More	precisely,	let	𝑛	be	a	node	in	pathway	𝑃..	Its	perturbation	factor,	𝑃𝐹 𝑛, 𝑃. 	can	be	defined	as:	
 𝑃𝐹 𝑛, 𝑃. = Δ𝐸 𝑛 + 4∈6 7,89 𝛽 𝑢, 𝑛;∈< 4,89 𝛽 𝑢, 𝑑 ⋅ 𝑃𝐹 𝑢, 𝑃. , (1) 
where	Δ𝐸 𝑛 	is	 the	 Log-Fold-Change	 computed	 for	 the	 node	𝑛 ,	𝑈 𝑛, 𝑃. 	and	𝐷 𝑛, 𝑃. 	are	 the	 set	 of	
upstream	and	downstream	nodes	of	𝑛	in	pathway	𝑃. 	respectively,	 and	𝛽 𝑢, 𝑛 	is	 a	 function	 that	 indicates	
the	strength	and	type	of	interaction	between	genes	𝑢	and	𝑛.	In	particular,	negative	values	of	𝛽	indicate	an	
inhibitory	effect,	while	positive	values	an	activating	one.	To	ensure	that	the	perturbation	coming	from	an	
upstream	 node	 is	 divided	 to	 its	 downstream	 ones,	 proportionally	 to	 the	 strength	 of	 their	 interactions,	
without	 altering	 the	 total	 perturbation,	 a	 normalization	 is	 applied	 dividing	 by	 the	 sum	 of	 the	 weights	
absolute	 values.	 By	 exploiting	 the	methodology	 described	 in	 Draghici	 et	 al.	 [26]	 we	 compute	 an	 impact	
factor,	𝐼𝐹 𝑃. ,	which	reflects	the	importance	of	the	changes	observed	in	a	pathway,	as:	
 𝐼𝐹 𝑃. = log 1𝑝 𝑃. + 7∈89 𝑃𝐹 𝑛, 𝑃.Δ𝐸 ⋅ 𝑁;G 𝑃. , (2) 
where	𝑝 𝑃. 	is	the	probability,	calculated	using	an	hyper-geometric	distribution,	of	obtaining	a	number	of	
differentially	expressed	nodes	at	least	equal	to	the	observed	one	in	𝑃.;	 Δ𝐸 	is	the	mean	Log-Fold-Change	in	𝑃.;	finally,	𝑁;G 𝑃. 	represents	the	number	of	differentially	expressed	nodes	in	the	pathway. 
Our	methodology	takes	also	advantage	of	 the	accumulation	 (or	accumulator)	as	described	by	Tarca	et	al.	
[27].	Such	a	methodology	has	been	revised	to	take	into	account	the	addition	of	miRNAs.	In	order	to	do	so,	
first	we	need	to	compute	two	partial	accumulators,	𝐴𝑐𝑐J.K 𝑃. 	and	𝐴𝑐𝑐LG7G 𝑃. ,	which	take	 into	account	
the	perturbation,	respectively,	of	miRNAs	and	genes:	
 𝐴𝑐𝑐J.K 𝑃. = J∈89M 𝑃𝐹 𝑚, 𝑃. − Δ𝐸 𝑚 , (3) 
 
 𝐴𝑐𝑐LG7G 𝑃. = L∈89P 𝑃𝐹 𝑔, 𝑃. − Δ𝐸 𝑔 , (4) 
where	𝑃.J	and	𝑃.L	are	the	sets	of	miRNAs	and	genes	present	in	𝑃.,	respectively. 
Therefore,	in	equations	3	and	4,	we	sum	the	perturbations	of	all	miRNAs	(𝑃.J)	and	genes	(𝑃.L)	in	pathway	𝑃.,	 addressing	 the	 dominant	 effect	 of	 the	 expression	 change	 in	 the	 PF	 computation	 by	 subtracting	 such	
values.	 We	 can	 now	 compute	 total	 perturbation	 accumulation,	𝐴𝑐𝑐 𝑃. ,	 which	 measures	 whether	 the	
pathway	is	likely	activated	or	inhibited.	The	introduction	of	miRNAs	in	our	model	addresses	the	necessity	to	
take	into	account	the	fact	that	an	increased	(decreased)	expression	of	such	elements	results	in	an	inhibition	
(activation)	of	the	pathway.	We	compute	𝐴𝑐𝑐 𝑃. 	as:	
 𝐴𝑐𝑐 𝑃. = 𝐴𝑐𝑐LG7G 𝑃. − 𝐴𝑐𝑐J.K 𝑃. − 𝐸 𝐴𝑐𝑐 𝑃. , (5) 
where	𝐸 𝐴𝑐𝑐 𝑃. 	is	an	estimate	of	the	expected	value	of	the	distribution	of	all	accumulators	computed	for	
pathway	𝑃.,	as	explained	below. 
P-value	 estimation	 is	 then	 performed	 by	 combining	 the	 Z-scores,	 computed	 through	 an	 inverse	
Standardized	 Normal	 distribution,	 associated	 to	 two	 probabilistic	 terms:	 the	 first	 is	 the	 probability	 of	
obtaining	 by	 chance	 a	 number	 of	 differentially	 expressed	 genes	 in	 the	 pathway	 at	 least	 equal	 to	 the	
observed	one,	while	the	second	consists	 in	the	probability	of	observing	by	chance	an	accumulator	higher	
than	 the	 computed	one.	The	 first	 term	corresponds	 to	𝑝 𝑃. 	introduced	 in	equation	2.	 The	 second	 term,	
instead,	has	to	be	estimated	through	a	permutation	test.	 In	such	a	test,	we	assign,	to	a	random	group	of	
genes	 in	 the	 pathway	 in	 question,	 a	 Log-Fold-Change	 selected	 randomly	 from	 the	 input	 ones,	 so	 as	 to	
compute	 a	 random	 accumulator.	 The	 procedure	 is	 repeated	 several	 times	 and	 the	 final	 probability	 is	
estimated	as	the	ratio	between	the	number	of	random	accumulators	greater	than	𝐴𝑐𝑐 𝑃. 	and	the	number	
of	repetitions	performed.	In	our	experiments,	the	repetitions	were	set	to	2000	in	order	to	obtain	maximum	
precision	up	to	two	decimal	places. 
At	this	stage	we	are	also	able	to	estimate	expected	value	𝐸 𝐴𝑐𝑐 𝑃. 	as	 the	median	value	of	 the	random	
accumulators.  
Therefore,	 the	 final	 result	 of	 our	 algorithm	 consists	 of	 a	 list	 of	 pathways	 along	with	 their	 impact	 factor,	
accumulator	and	adjusted	p-values.	Such	list	is	sorted	by	p-value	and	Acc. 
Expression	Data	Sources	
To	perform	a	comprehensive	test	of	our	algorithm,	we	exploited	expression	data	provided	by	The	Cancer	
Genome	 Atlas	 (beginning	 of	 2014).	We	 downloaded	 all	 patient	 expression	 profiles	 of	 genes	 (RNASeqV2	
obtained	 through	 platforms	 Illumina	 Genome	 Analyzer	 and	 Illumina	 HiSeq)	 and	 miRNAs	 (miRNASeq	
obtained	 through	 platforms	 Illumina	Genome	Analyzer	 and	 Illumina	 HiSeq).	 The	 initial	 dataset	was	 then	
filtered	by	 removing	all	patients	 for	which	one	of	 the	 two	 types	of	expression	was	unavailable.	We	 then	
eliminated	all	tumor	samples	for	which	no	healthy	controls	were	available.	By	applying	such	a	procedure,	
we	built	 a	dataset	of	3,053	expression	profiles	 (2,721	case	 samples	and	332	control	 samples)	of	patients	
affected	by	10	distinct	tumor	pathologies	(see	Table	1	for	more	details).	Case	samples	were	further	divided	
by	disease	stage. 
To	run	our	algorithm,	we	performed	a	differentially	expressed	genes	analysis	by	using	the	RNASeq	pipeline	
based	on	Limma	[45].	The	expression	matrices	for	each	disease	were	firstly	normalized	by	using	the	Voom	
algorithm	 [46],	 then	 a	 linear	model	was	 trained	with	 Limma	 and	 differentially	 expressed	 genes	 for	 each	
stage	 of	 the	 disease	were	 extracted	 along	with	 their	 Log-Fold-Change.	 In	 our	 analysis	we	 considered	 as	
differentially	expressed	only	those	genes	for	which	an	adjusted	p-value	was	lower	than	0.01	as	computed	
by	Limma.	
In	order	 to	correctly	ascertain	PARADIGM	performance,	 for	each	 tumor	sample	we	also	downloaded	and	
processed	copy	number	variation	(CNV)	as	shown	in	Vaske	et	al.	2010	[28]. 
Performance	Assessment	
To	compare	our	algorithm	with	other	methodologies,	PARADIGM	[28],	SPIA	[27]	and	Micrographite	[30],	we	
used	the	decoy	pathway	technique	introduced	in	Vaske	et	al.	2010	[28].	For	each	pathway	in	our	internal	
database,	we	built	a	decoy	one	obtained	by	maintaining	the	same	structure	and	substituting	each	gene	(or	
miRNA)	with	one	randomly	chosen	from	the	set	of	all	possible	genes.	As	 in	Vaske	et	al.	2010	[28],	all	 the	
complexes	and	abstract	processes	were	kept	unchanged.	After	the	execution	of	the	three	algorithms,	the	
pathways	were	 classified	 by	 each	method	 and	 the	 fraction	 of	 real	 pathways	 versus	 the	 total	 number	 of	
pathways	considered	was	computed.	The	higher	the	fraction	of	real	pathways,	the	better	the	ability	of	an	
algorithm	to	extract	biologically	sound	results.	Lastly,	to	achieve	a	fair	comparison	with	SPIA,	we	chose	the	
same	𝛽	function	 as	 Tarca	 et	 al.	 2009	 [27]:	𝛽 𝑢, 𝑛 = 1	for	 all	 interactions	 that	 increase	 node	 expression	
level,	𝛽 𝑢, 𝑛 = −1	for	 those	 that	 have	 the	 effect	 of	 decreasing	 node	 expression	 level,	𝛽 𝑢, 𝑔 = 0	for	
irrelevant	 ones.	 However,	 the	𝛽	function	 introduces	 a	 huge	 concealed	 potential	 in	MITHrIL,	which	 paves	
the	way	for	possible	future	extensions.	
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Tables	
	
Code		 Cancer	Type		 Control	Samples	 Case	Samples	 Case	Samples	Categories	
BLCA		 Bladder	Urothelial	Carcinoma		 19	 193	 Stage	I,	II,	III,	IV	
BRCA		 Breast	invasive	carcinoma		 86	 642	 Stage	I,	II,	III,	IV,	X	
COAD		 Colon	adenocarcinoma		 8	 389	 Stage	I,	II,	III,	IV	
KICH		 Kidney	Chromophobe		 25	 66	 Stage	I,	II,	III,	IV	
KIRC		 Kidney	renal	clear	cell	carcinoma		 71	 224	 Stage	I,	II,	III,	IV	
LUAD		 Lung	adenocarcinoma		 19	 388	 Stage	I,	II,	III,	IV	
LUSC		 Lung	squamous	cell	carcinoma		 37	 247	 Stage	I,	II,	III,	IV	
PRAD		 Prostate	adenocarcinoma		 50	 191	 Category	6,	7,	8,	9,	10	
READ		 Rectum	adenocarcinoma		 3	 150	 Stage	I,	II,	III,	IV	
UCEC		 Uterine	Corpus	Endometrial	Carcinoma		 14	 231	 Stage	I,	II,	III,	IV	
	 All	Samples		 332	 2721	 	
Table	1	List	of	cancer	types	extracted	from	The	Cancer	Genome	Atlas	(TCGA)	with	their	codes,	number	of	case	and	control	samples,	
and	Subcategories.	
	 	 Perturb.	Of	Random	Nodes	 Endpoints	 Pathway-level	Statistics	
Data		 Log-FC	 MITHrIL	 MITHrIL	no	
miRNA	
MITHrIL	 MITHrIL	
no	miRNA	
PARADIGM	MITHrIL		
Acc.	
SPIA	
Acc.	
PARADIGM	
Scores	
BLCA		 3.11%	 9.59%	 6.58%	 1.55%	 2.60%	 2.08%	 12.95%	 49.74%	 82.38%	
BRCA		 1.86%	 2.12%	 3.97%	 1.09%	 2.00%	 2.34%	 13.08%	 8.25%	 73.05%	
COAD		 2.31%	 0.00%	 7.81%	 0.00%	 0.00%	 3.10%	 0.77%	 0.00%	 32.90%	
KICH		 3.03%	 1.67%	 3.03%	 0.00%	 0.00%	 3.03%	 4.54%	 3.03%	 31.81%	
KIRC		 3.12%	 2.68%	 2.77%	 1.79%	 2.68%	 3.13%	 5.80%	 2.67%	 35.26%	
LUAD		 4.89%	 0.03%	 8.61%	 1.80%	 2.06%	 5.41%	 4.38%	 2.83%	 64.43%	
LUSC		 6.07%	 1.78%	 6.92%	 1.21%	 2.02%	 6.91%	 5.26%	 4.04%	 71.54%	
PRAD		 0.00%	 0.37%	 1.26%	 0.00%	 0.00%	 0.52%	 2.61%	 30.89%	 18.94%	
READ		 3.33%	 0.00%	 9.40%	 0.00%	 0.00%	 4.00%	 0.66%	 0.00%	 96.66%	
UCEC		 1.73%	 1.39%	 1.13%	 0.00%	 0.43%	 0.09%	 4.32%	 1.29%	 46.32%	
Total		 2.90%	 1.75%	 5.38%	 0.90%	 1.50%	 3.20%	 6.40%	 8.80%	 57.60%	
Table	2	Classification	results	of	tumor	samples	in	our	dataset	obtained	training	PAMR	algorithm	by	means	of	Log-Fold-Change,	SPIA	
total	accumulation,	Paradigm	scores,	MITHrIL	accumulators,	and	MITHrIL	endpoint	perturbations.	Each	element	in	the	table	
corresponds	to	the	classification	error	for	a	specific	cancer	type	using	one	algorithm.	Despite	the	reference	classification	based	on	
Log-Fold-Change	yields	a	low	average	error	(2.90%),	the	employment	of	perturbations	computed	for	each	endpoint	provides	a	
significant	improvement	in	the	classification	accuracy.	
	 	
Figures	
	
	
Figure	1	Performances	comparison	between	MITHrIL,	SPIA,	and	PARADIGM	by	means	of	 the	average	area	under	 the	ROC	curves.	
Each	box	in	the	figure	represents	the	variability	range	of	AUC	values	for	a	specific	methodology.	
	
	
Figure	2	Significance	of	 the	addition	of	miRNA	 in	our	model	by	means	of	a	comparison	of	 the	percentages	of	 correctly	predicted	
endpoints	for	each	sample	between	our	method	with	and	without	miRNAs.	Each	box	in	the	figure	represents	the	variability	range	of	
the	 percentage	 of	 correctly	 predicted	 endpoints	 for	 the	 patients	 of	 a	 specific	 tumor	 type.	 A	 prediction	 is	 correct	 when	 the	
deregulation	observed	 in	the	original	data	correspond	to	the	one	 inferred	by	our	algorithm.	Namely,	 the	sign	of	an	endpoint	 log-
Fold-Change	corresponds	to	the	sign	of	its	perturbation	value.	
